Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial
International Journal of Molecular Sciences · 27.07.2023 · 24 (15) · 12063
DOI: 10.3390/ijms241512063 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.07.2023. Verfasst von Graziamaria Corbi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences, University of Naples "Federico II", 80138 Naples, Italy. Hauptthemen laut MEDLINE: Postmenopause, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was not supported by any industrial funds..
Abstract (Originalsprache)
Estrogen deficiency is a major cause of loss of postmenopausal bone mineral density (BMD). This study aimed to evaluate the effects of equol and resveratrol on bone turnover biomarkers in postmenopausal women. Sixty healthy postmenopausal women were randomly assigned to receive 200 mg fermented soy containing 10 mg equol and 25 mg resveratrol or a placebo for 12 months. Whole-body BMD and bone turnover biomarkers, such as deoxypyridinoline (DPD), tartrate-resistant acid phosphatase 5b (TRACP-5b), osteocalcin, and bone-specific alkaline phosphatase (BAP), were measured at baseline and after 12 months of treatment. At the end of treatment, DPD, osteocalcin, and BAP significantly improved in the active group (p < 0.0001 for all) compared to the placebo group. Conversely, TRACP-5b levels were unaffected by supplementation (p = 0.051). Statistically significant changes in the concentrations of DPD (p < 0.0001), osteocalcin (p = 0.0001), and BAP (p < 0.0001) compared to baseline were also identified. Overall, the intervention significantly increased BMD measured in the whole body (p = 0.0220) compared with the placebo. These data indicate that the combination of equol and resveratrol may positively modulate bone turnover biomarkers and BMD, representing a potential approach to prevent age-related bone loss in postmenopausal women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medical Sciences, University of Naples "Federico II", 80138 Naples, Italy.
- Farcoderm S.r.l., 27028 San Martino Siccomario, Italy.
- Department of Medicine Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, 84081 Baronissi, Italy.
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, 35131 Padua, Italy.
- Department of Medicine and Health Sciences "V. Tiberio", University of Molise, 86100 Campobasso, Italy.
ORCID-Profile: Graziamaria Corbi, Vincenzo Nobile, Valeria Conti, Alessandro Cannavo, Vincenzo Sorrenti, Alessandro Medoro, Giovanni Scapagnini, Sergio Davinelli
Förderung
- This study was not supported by any industrial funds.
Zitieren
APA
Corbi, G., Nobile, V., Conti, V., Cannavo, A., Sorrenti, V., Medoro, A., Scapagnini, G., & Davinelli, S. (2023). Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial. International Journal of Molecular Sciences, 24(15), 12063. https://doi.org/10.3390/ijms241512063
Vancouver
Corbi G, Nobile V, Conti V, Cannavo A, Sorrenti V, Medoro A, et al. Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial. International Journal of Molecular Sciences. 2023;24(15):12063. doi:10.3390/ijms241512063
BibTeX
@article{Corbi2023,
author = {Corbi, Graziamaria and Nobile, Vincenzo and Conti, Valeria and Cannavo, Alessandro and Sorrenti, Vincenzo and Medoro, Alessandro and Scapagnini, Giovanni and Davinelli, Sergio},
title = {Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {15},
pages = {12063},
doi = {10.3390/ijms241512063}
}
EUVIMED